• Berberine, Tuft Cells, and Estrogen-Deficiency Bone Loss

  2026-09-29

  A 2026 reference study identifies a gut–bone mechanism in which berberine increases intestinal butyrate, activates GPR41-associated signaling, and expands tuft cells to improve barrier function and osteoimmune balance during estrogen deficiency. Its combination of ovariectomized rodents, microbiome profiling, immune analysis, genetic models, and intestinal organoids provides a mechanistic framework for preclinical postmenopausal osteoporosis research.

• Endogenous Melatonin in LPS-Activated Macrophages

  2026-09-29

  The reference study identifies an inducible macrophage melatonin response in which LPS activates Aanat transcription through the TLR4/TRIF pathway, with IRF3 acting as a principal transcriptional regulator. Its findings suggest that endogenous melatonin is not merely a byproduct of activation: it can restrain M1-like polarization, oxidative stress, and apoptosis during inflammatory stimulation.

• Sodium Oxamate: From Flux to Cell-State Causality

  2026-09-28

  Sodium Oxamate is more than an LDH-A probe: it can help distinguish glycolytic flux, lactate signaling, and tissue outcomes. This evidence-led guide connects cancer metabolism research with a mechanistically important microglial white matter injury study while defining practical assay decisions and limitations.

• EPI-001 Workflow for AR N-Terminal Domain Research

  2026-09-28

  EPI-001 offers a way to probe androgen receptor signaling through the receptor’s N-terminal domain, including questions that ligand-binding-domain inhibitors may not resolve. This workflow connects the compound’s established prostate-cancer research context with emerging TNBC findings, while separating published observations from practical assay starting points.

• Dual Methylation Drives EGFR-TKI Resistance

  2026-09-26

  This study links DNA 5-methylcytosine and RNA m5C regulation to alternative splicing of MZF1, shifting expression toward a zinc-binding–deficient isoform associated with EGFR-TKI resistance. Its findings identify a coordinated epigenetic axis that may be useful for resistance research and biomarker development, while requiring further validation before clinical application.

• Tobramycin Research: Interpreting Aminoglycoside Assays

  2026-09-25

  Tobramycin is an aminoglycoside antibiotic used in research on bacterial protein synthesis and susceptibility. This article examines how historical comparator data can guide modern assay interpretation—without confusing in-vitro activity with clinical effectiveness.

• Alexa Fluor 488 conjugated secondary antibody for DMV

  2026-09-25

  Map goat-primary targets in coronavirus replication-organelle models with a bright green fluorescent readout, while keeping the distinction clear between DMV organization and ultrastructural proof. This guide translates FXR phase-separation findings into practical immunofluorescence, Western blot, and flow-cytometry workflows using HyperFluor™ 488.

• CLEC5A and ISG20 in Atherosclerosis: Causal Evidence

  2026-09-24

  Zhang et al. combined transcriptomic and eQTL evidence with Mendelian randomization, then examined candidate genes in ox-LDL-stimulated macrophages and atherosclerotic mouse models. Their results associate CLEC5A and ISG20 with atherosclerosis risk and identify ISG20 as a prominent plaque-associated signal, while leaving important questions about effect size, mechanism, and generalizability for follow-up studies.

• EZ Cap™ EPO mRNA for Neurorepair Research

  2026-09-24

  Use human erythropoietin mRNA to build reproducible protein-expression and erythropoiesis assays, then extend the workflow to targeted neuroinflammation models. A recent spinal cord injury study offers a delivery strategy to investigate—not a claim that this research product is itself a therapeutic formulation.

• Nadolol (SQ-11725): PK-Aware Cardiovascular Research

  2026-09-23

  Nadolol research becomes more interpretable when receptor pharmacology is considered alongside compound exposure and transport. This translational perspective connects beta-adrenergic signaling with practical assay design—and explains why disease-state pharmacokinetic findings from another research area should inform experimental questions, not be assumed to transfer directly.

• EPI-001: Androgen Receptor N-Terminal Inhibitor

  2026-09-23

  EPI-001 is an androgen receptor N-terminal domain inhibitor for separating ligand-independent AR biology from downstream growth, EMT, and motility phenotypes. This workflow translates evidence from prostate cancer and AR-positive TNBC models into practical dosing, controls, readouts, and troubleshooting decisions.

• SAR131675: VEGFR-3 Biology for Translational Research

  2026-09-22

  A thought-leadership analysis of SAR131675 as a selective VEGFR-3 inhibitor, covering its ATP-competitive mechanism, experimental validation, translational positioning, model-selection strategy, and limitations for cancer, lymphangiogenesis, angiogenesis, fibrosis, and kidney-disease research.

• CD80 mRNA: A Translational Lever for Costimulation

  2026-09-22

  Transient CD80 expression offers a controllable way to study antigen-presenting-cell costimulation and its effect on T-cell function. This thought-leadership article connects the clinical logic of mRNA-augmented CAR T-cell therapy with practical assay design using EZ Cap™ Mouse CD80 mRNA (m1Ψ, HA tag), while clearly separating research hypotheses from clinical evidence.

• VZV gE Mutations Improve mRNA Vaccine Responses

  2026-09-21

  The reference study tested whether altering the carboxyl-terminal trafficking motifs of varicella-zoster virus glycoprotein E could improve the immunogenicity of LNP-formulated mRNA vaccines. Its combined C-terminal mutant produced the most consistent humoral and cellular responses, supporting antigen-trafficking engineering as a strategy for candidate varicella and zoster vaccines.

• Pretomanid and Dual Terminal Oxidase Inhibition

  2026-09-21

  The reference study identifies simultaneous inhibition of the cytochrome bcc:aa3 and cytochrome bd respiratory branches as a central feature of pretomanid activity against Mycobacterium tuberculosis. Its combination data support pairing pretomanid with telacebec and, in a triple regimen, ND-011992 to improve killing across replicating and antibiotic-tolerant populations while limiting resistance emergence.

8344 records 1/557 page Next 12345 下5页 Last page